Asada Ashlee M, Kahwash Rami, Trovato Vincenzo
Division of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Division of Cardiovascular Medicine, The Ohio State University, Columbus, OH, USA.
Curr Cardiol Rep. 2025 Jan 23;27(1):38. doi: 10.1007/s11886-024-02184-6.
Eosinophilic myocarditis (EM) is a rare and heterogeneous form of inflammatory heart disease that can present with a wide range of severity. Current literature is limited to case reports or small case series that outline the evaluation process, disease course, and the nonstandardized treatments trialed. This review aims to concisely summarize the current literature on EM including an update on maintenance therapy for refractory or recurrent disease.
In the last several years, several observational studies have reported the clinical benefit of mepolizumab and benralizumab in refractory EM. EM is a complex and heterogenous cause of inflammatory heart disease with a wide range of etiologies and presentations. Treatment of this disease has not been standardized as there are no large scale trials quantifying benefit of any specific therapy regimen. Targeted biologics show promise in observational studies; therefore, prospective studies are needed to quantify this benefit in EM.
嗜酸性粒细胞性心肌炎（EM）是一种罕见的、异质性的炎症性心脏病，严重程度范围广泛。目前的文献仅限于病例报告或小型病例系列，概述了评估过程、疾病进程以及试验的非标准化治疗方法。本综述旨在简要总结当前关于EM的文献，包括难治性或复发性疾病维持治疗的最新情况。
在过去几年中，多项观察性研究报告了美泊利单抗和贝那利单抗在难治性EM中的临床益处。EM是一种复杂且异质性的炎症性心脏病病因，病因和表现形式多种多样。由于没有大规模试验量化任何特定治疗方案的益处，该疾病的治疗尚未标准化。靶向生物制剂在观察性研究中显示出前景；因此，需要进行前瞻性研究以量化其在EM中的益处。
